Antibody-Drug Conjugates in HER2+ Breast Cancer | Supplements And Featured Publications

Antibody-Drug Conjugates in HER2-Positive Breast Cancer

August 14, 2020

Novel antibody-drug conjugates introduce promising options for the management of patients with HER2-positive breast cancer; however, management of drug-related toxicities and optimal sequencing of HER2-targeted therapies remains an ongoing challenge.